Overview

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2018-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
PRA Health Sciences